Resources

Pharmaceutical and Biologics Manufacturer Services

Frier Levitt has tools to help pharmaceutical and biotech companies control the narrative on drug pricing, understand and follow the maze of existing and newly…

Download Pharmaceutical and Biologics Manufacturer Services PDF

Related Services

Pharmaceutical Manufacturers
Pharmaceutical Wholesalers, Distributors, and GPOs

Topics

Pharmacy Law
Manufacturers
Biotech Companies
Pharmaceutical Manufacturers

Life Sciences & Pharmacy

Call Us Now

Pharmaceutical and Biologics Manufacturer Services

New Jersey Governor Mikie Sherrill Takes Aim at Pharmacy Benefit Managers

Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny

PBMs Are Targeting Alabama Hospitals with Discriminatory Networks: What 340B Covered Entities Need to Know

A.J. Barbarito Featured in MedCity News: “It Took Years for Congress to Enact PBM Transparency, Delinking. What About Vertical Integration?”

Plan Sponsor Alert: Recent ERISA Decisions Increase Employer Liability Risk for Excessive Fees Paid to Vendors, Brokers, and Service Providers, Including PBMs

Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes

The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry

From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs

Pharmaceutical and Biologics Manufacturer Services

Related Insights

New Jersey Governor Mikie Sherrill Takes Aim at Pharmacy Benefit Managers

Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny

PBMs Are Targeting Alabama Hospitals with Discriminatory Networks: What 340B Covered Entities Need to Know

A.J. Barbarito Featured in MedCity News: “It Took Years for Congress to Enact PBM Transparency, Delinking. What About Vertical Integration?”

Plan Sponsor Alert: Recent ERISA Decisions Increase Employer Liability Risk for Excessive Fees Paid to Vendors, Brokers, and Service Providers, Including PBMs

Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes

The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry

From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs